title: Receptor tyrosine kinases in cancer escape from BRAF inhibitors.
authors.affiliation: Division of Dermatology, Department of Medicine, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, 52-121 CHS, 10833 Le Conte Ave, Los Angeles, CA 90095-1750, USA. rlo@mednet.ucla.edu
authors.forename: Roger S
authors.initials: RS
authors.lastname: Lo
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000201:enzymology*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D000069347:Erlotinib Hydrochloride; D006801:Humans; D007211:Indoles / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D008545:Melanoma / Q000188:drug therapy / Q000201:enzymology*; D051379:Mice; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D011799:Quinazolines / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D013449:Sulfonamides / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D014183:Transplantation, Heterologous; D000077484:Vemurafenib
chemical_list: D007211:Indoles; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D013449:Sulfonamides; D000077484:Vemurafenib; D000069347:Erlotinib Hydrochloride; D020794:Receptor Protein-Tyrosine Kinases; D048493:Proto-Oncogene Proteins B-raf